Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.Allergy · 2026
   Guideline
2. Emerging IgE and non-IgE targeted therapies for chronic urticaria.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
   Review
3. Biopredictors for Omalizumab Response in Patients With Chronic Spontaneous Urticaria.The journal of allergy and clinical immunology. In practice · 2026
   Article
4. Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond.The journal of allergy and clinical immunology. In practice · 2026
   Review
5. Specialist care improves diagnosis and treatment for patients with chronic spontaneous urticaria: A real-world survey.The journal of allergy and clinical immunology. Global · 2026
   Article
6. Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
   Review
7. Beyond Antihistamines: How Biologic and Small-Molecule Therapies Are Transforming Chronic Spontaneous Urticaria Care in Adults.Clinical drug investigation · 2025
   Review
8. [Severe anaphylaxis following administration of omalizumab].Dermatologie (Heidelberg, Germany) · 2025
   Article
9. Vaccine-Induced Anti-IgE Antibodies Neutralize Free IgE but Fail to Bind and Activate Mast Cell-Displayed IgE.Allergy · 2025
   Article
10. Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case-control study.Archives of dermatological research · 2025
    Article
11. Reduction of circulating IgE and allergens by a pH-sensitive antibody with enhanced FcγRIIb binding.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
12. Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?The World Allergy Organization journal · 2024
    Article
13. Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.Allergologie select · 2024
    Review
14. Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status.Dermatology and therapy · 2023
    Review
15. Clinical Response to Low-dose Omalizumab Treatment in Chronic Spontaneous Urticaria: A Retrospective Study of 179 Patients.Acta dermato-venereologica · 2023
    Article
16. Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review.Clinical reviews in allergy & immunology · 2022
    Review
17. IgE glycans promote anti-IgE IgG autoantibodies that facilitate IgE serum clearanceFrontiers in immunology · 2022
    Article
18. Biologic drugs in chronic spontaneous urticaria.Acta bio-medica : Atenei Parmensis · 2021
    Review
19. Expert consensus on the use of omalizumab in chronic urticaria in China.The World Allergy Organization journal · 2021
    Review
20. Biologics for atopic diseases: Indication, side effect management, and new developments.Allergologie select · 2021
    Review

Corrections and comments

• Erratum for
  Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.2015

Authors and funding

12 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.